Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.

Arefin NS, Moon J, Roller AB, Aung MH

Open source

DOI
10.3389/fonc.2026.1872343
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1872343,
  title = {Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.},
  author = {Arefin NS and Moon J and Roller AB and Aung MH},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1872343},
  url = {https://doi.org/10.3389/fonc.2026.1872343}
}

RIS

TY  - JOUR
TI  - Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.
AU  - Arefin NS
AU  - Moon J
AU  - Roller AB
AU  - Aung MH
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1872343
UR  - https://doi.org/10.3389/fonc.2026.1872343
ER  - 

APA

NS, A., J, M., AB, R., & MH, A. (2026). Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1872343

Source records